-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $28

Benzinga·08/06/2026 13:14:29
Listen to the news
Citizens analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and raises the price target from $25 to $28.